Table 1.
Demographical and clinical characteristics of the patients and HV at sampling.
| Patient | Age | Gender | Disease duration (years) | Disease type | EDSS | In the preceding year | Death-sampling interval | Cause of death | Treatments history | Last treatment-sampling interval | HLA typing | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Gd+ lesions | Number of relapses | |||||||||||
| MS 1 | 45 | M | 12 | SP | 8.5 | 0 | 0 | 12 h | Lung cancer | Azathioprine-Cyclophosphamide | 24 months | A*0301/2402 |
| Mitoxantrone-Interferon | B*0702(0761)/1402 | |||||||||||
| Methotrexate | DRB1*0102/1501 | |||||||||||
| DQB1*0501/0602 | ||||||||||||
| MS 2 | 66 | F | 10 | PP | 7.5 | 0 | 0 | 6 h | Pulmonary infection | None | Treatment naive | A*0201/3201 |
| B*0702(0761)/3501(3542) | ||||||||||||
| DRB1*1101/1302 | ||||||||||||
| DQB1*0301(0322)/0604(0639) | ||||||||||||
| MS 3 | 54 | F | 23 | PP | 9 | 0 | 0 | 8 h | Pulmonary infection | Mitoxantrone | 120 months | A*0101/1101 |
| B*0801/4403 | ||||||||||||
| DRB1*0301(0350)/1301 | ||||||||||||
| DQB1*0201/0603 | ||||||||||||
| MS 4 | 33 | M | 1 | RR | 4 | 6 | 2 | N/A | N/A | None | Treatment naive | – |
| MS 5 | 33 | F | 10 | RR | 2.5 | 0 | 2 | N/A | N/A | Glatiramer acetate | 3 months | – |
| MS 6 | 39 | F | 20 | RR | 4 | 1 | 1 | N/A | N/A | Azathioprine | 5 months | – |
| MS 7 | 48 | M | 26 | RR | 3 | 1 | 1 | N/A | N/A | MMF | 2 months | – |
| HV 1 | 47 | F | – | – | – | – | – | – | – | – | – | – |
| HV 2 | 28 | F | – | – | – | – | – | – | – | – | – | – |
| HV 3 | 37 | F | – | – | – | – | – | – | – | – | – | – |
| HV 4 | 52 | M | – | – | – | – | – | – | – | – | – | – |
For HLA typing, the number in parenthesis is the rare alleles that cannot be excluded from the typing. Gd, gadolinium; MS, multiple sclerosis; F, female; M, male; N/A, not applicable; HV, healthy volunteers; EDSS, expanded disability status scale; MMF, mycophenolate mofetil.